source
- CVS adds Lilly’s Foundayo and Zepbound to formularies, leveling GLP-1 market with NovoCVS Caremark announced it will place Eli Lilly’s new oral GLP-1 drug Foundayo on its formulary starting June 1 and will restore the injectable Zepbound as a preferred option from Oct 1. The change…
- AbbVie receives FDA approval for ultra-rare blood cancer ADC acquired from ImmunoGenAbbVie announced that the U.S. Food and Drug Administration has granted approval for an antibody-drug conjugate targeting an ultra-rare, aggressive form of blood cancer. The therapy was obtained t…